seeing ;5000 patients per year. 1 Given our prevalence of a diagnosis of AA in 0.63% (3633/572,617) of dermatology patients of all ages, we estimate that 302,337 patients with AA visit US dermatology practices each year. A 1992 study reported a similar nationwide prevalence of 306,000 AA patients. 2 Our study found that pediatric AA patients represented 18.1% of AA patients of all ages. Thus, we estimate that ;54,000 pediatric AA patients visit dermatology offices per year. McMichael et al reported that 16% of total visits for AA involved patients 0-19 years of age, 3 and Safavi et al found that 27.7% of 292 AA patients were 0-19 years of age. 4 The rate of 5000 dermatology patients per year per dermatologist noted above can be viewed as 21 patients per day (assuming a 5-day work week 52 weeks/year) or 1000 patients in ;2.4 months. 3 On the basis of our data, pediatric patients represent 126 of these 1000 patients; 10 of 126 will have a hair condition, and 1 of 126 will have AA. Thus, on average, 1 pediatric patient with AA will appear for treatment at a private dermatology office in the United States every 2.4 months; this single AA patient is 1.25 times more likely to be a girl than a boy. 
Lack of an association between alopecia areata and visceral or hematopoietic cancers
To the Editor: Alopecia areata (AA) is a polygenic, patchy nonscarring hair loss that presents on the scalp and body that drastically affects patients' quality of life. 1 The pathogenesis of AA remains elusive, though T-lymphocyteemediated inflammation and various environmental stressors play a role. The association between AA and various autoimmune diseases has been explored in several studies. 1 Recently, studies found lower rates of nonmelanoma skin cancers and a trend toward decreased melanoma among AA patients.
2,3 To our knowledge, no studies have assessed the association between AA and systemic malignancy. The current popularity of Janus kinase inhibitors for AA highlights the need to further investigate this association because they theoretically increase the risk for malignancy. 4 This research letter provides a review of the Cleveland Clinic Alopecia Registry specifically looking at all cancers present in patients with AA to add to the growing literature base characterizing this multifactorial disease.
A retrospective chart review was performed with the Cleveland Clinic Alopecia Registry on AA patients with varying degrees of severity who sought treatment during 2005-2016 (n ¼ 636). A control group of age-matched patients given diagnoses of seborrheic dermatitis (SD) without hair loss was randomly selected (n ¼ 215). Hair loss specialists assessed the control group for the absence of hair loss to ensure validity. Data were collected on sex, age, and presence of visceral cancers. The inclusion criterion was diagnosis of AA or SD by a Cleveland Clinic dermatologist. The presence of systemic cancers in the AA group and the control group was determined by manual chart review. Demographic and clinical variables were compared using t-test, 2 test, and Fisher's exact test. Significance was considered at an ¼ 0.05.
In our study population of 636 AA patients, mean age was 39.72 6 18.91 years, and the population was predominantly women (71.7%, Table I ). There was no calculable difference in cancer incidence between AA and the control group. Thyroid cancers and leukemia were noted only in the AA group, and lung cancers were present only in the control group, although these findings were not deemed statistically significant because of the low number of patients. We hypothesized that the rates of systemic malignancy would be lower in AA because of the autoimmune nature of the disease. It is known that treatment of cancers with immune checkpoint inhibitors such as tumor necrosis factor , cytotoxic T-lymphocyteeassociated protein 4, and programmed cell death protein and ligand can induce AA. 5 Induction of AA was likely due to activation of the inflammatory response and exposure of hair follicle antigens leading to loss of immune privilege. 5 Our findings call for additional, larger studies to further validate the claim that AA does not affect the risk of developing systemic cancers. These findings could potentially aid in understanding the risks associated with AA.
Strengths of our study included the presence of hair-loss specialists and a detailed AA registry. The centralized AA registry had data that was manually entered, ensuring that the relevant data were obtained for all patients. The main limitation of this study was that the cancer incidence of the control group might have differed from the general population. 
